Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site
mi
from
Tampa, FL
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 096
mi
from
Atlanta, GA
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 096
mi
from
Atlanta, GA
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 10765
mi
from
Augusta, GA
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 10765
mi
from
Augusta, GA
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 1367
mi
from
Chicago, IL
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 1367
mi
from
Chicago, IL
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 1303
mi
from
Northbrook, IL
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 1303
mi
from
Northbrook, IL
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 7008
mi
from
Springfield, IL
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 7008
mi
from
Springfield, IL
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 55
mi
from
Des Moines, IA
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 55
mi
from
Des Moines, IA
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 56
mi
from
Scarborough, ME
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 56
mi
from
Scarborough, ME
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 024
mi
from
Boston, MA
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 024
mi
from
Boston, MA
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 7015
mi
from
Lansing, MI
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 7015
mi
from
Lansing, MI
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 10540
mi
from
Traverse City, MI
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 10540
mi
from
Traverse City, MI
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 39
mi
from
Golden Valley, MN
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 39
mi
from
Golden Valley, MN
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 10150
mi
from
Omaha, NE
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 10150
mi
from
Omaha, NE
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 10439
mi
from
Buffalo, NY
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 10439
mi
from
Buffalo, NY
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 10781
mi
from
Durham, NC
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 10781
mi
from
Durham, NC
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site
mi
from
Raleigh, NC
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site
mi
from
Cincinnati, OH
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 013
mi
from
Toledo, OH
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 013
mi
from
Toledo, OH
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 406
mi
from
Allentown, PA
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 406
mi
from
Allentown, PA
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 10183
mi
from
Philadelphia, PA
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 10183
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 10162
mi
from
Providence, RI
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 10162
mi
from
Providence, RI
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site
mi
from
Houston, TX
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 12279
mi
from
Milwaukee, WI
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 12279
mi
from
Milwaukee, WI
Click here to add this to my saved trials
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated:  4/8/2016
Teva Investigational Site 20033
mi
from
Buenos Aires,
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Status: Enrolling
Updated: 4/8/2016
Teva Investigational Site 20033
mi
from
Buenos Aires,
Click here to add this to my saved trials
Subthalamic Deep Brain Stimulation (DBS) in Parkinson's Disease
Evaluating Cortical Physiology Following Unilateral and Bilateral Subthalamic Deep Brain Stimulation in Parkinson's Disease
Status: Enrolling
Updated:  4/15/2016
University of Florida
mi
from
Gainesville, FL
Subthalamic Deep Brain Stimulation (DBS) in Parkinson's Disease
Evaluating Cortical Physiology Following Unilateral and Bilateral Subthalamic Deep Brain Stimulation in Parkinson's Disease
Status: Enrolling
Updated: 4/15/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Mapping Mood in the Subthalamic Nucleus in Parkinson's Disease (PD)
Mapping Mood in the Subthalamic Nucleus in PD
Status: Enrolling
Updated:  5/3/2016
University of Cincinnati, Movement Disorder Center
mi
from
Cincinnati, OH
Mapping Mood in the Subthalamic Nucleus in Parkinson's Disease (PD)
Mapping Mood in the Subthalamic Nucleus in PD
Status: Enrolling
Updated: 5/3/2016
University of Cincinnati, Movement Disorder Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Mapping Mood in the Subthalamic Nucleus in Parkinson's Disease (PD)
Mapping Mood in the Subthalamic Nucleus in PD
Status: Enrolling
Updated:  5/3/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Mapping Mood in the Subthalamic Nucleus in Parkinson's Disease (PD)
Mapping Mood in the Subthalamic Nucleus in PD
Status: Enrolling
Updated: 5/3/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Battery-preserving Stimulation Patterns for Deep Brain Stimulation
Battery-preserving Stimulation Patterns to Improve Symptoms in Parkinson's Disease and Essential Tremor
Status: Enrolling
Updated:  5/9/2016
Center for Movement Disorders and Neurorestoration
mi
from
Gainesville, FL
Battery-preserving Stimulation Patterns for Deep Brain Stimulation
Battery-preserving Stimulation Patterns to Improve Symptoms in Parkinson's Disease and Essential Tremor
Status: Enrolling
Updated: 5/9/2016
Center for Movement Disorders and Neurorestoration
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated:  6/15/2016
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated: 6/15/2016
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated:  6/15/2016
MD Clinical
mi
from
Hallandale, FL
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated: 6/15/2016
MD Clinical
mi
from
Hallandale, FL
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated:  6/15/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated: 6/15/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated:  6/15/2016
SNBL Clinical Pharmacology Center
mi
from
Baltimore, MD
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated: 6/15/2016
SNBL Clinical Pharmacology Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated:  6/15/2016
Parkinson's Movement Disorder Center of Maryland
mi
from
Elkridge, MD
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated: 6/15/2016
Parkinson's Movement Disorder Center of Maryland
mi
from
Elkridge, MD
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated:  6/15/2016
Neurology Consultants of Dallas, PA
mi
from
Dallas, TX
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated: 6/15/2016
Neurology Consultants of Dallas, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated:  6/15/2016
Walnut Hill Medical Center
mi
from
Dallas, TX
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated: 6/15/2016
Walnut Hill Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated:  6/15/2016
Pfizer Clinical Research Unit
mi
from
Brussels,
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Enrolling
Updated: 6/15/2016
Pfizer Clinical Research Unit
mi
from
Brussels,
Click here to add this to my saved trials
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
Status: Enrolling
Updated:  6/23/2016
Bastyr University
mi
from
Kenmore, WA
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
Status: Enrolling
Updated: 6/23/2016
Bastyr University
mi
from
Kenmore, WA
Click here to add this to my saved trials
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
Status: Enrolling
Updated:  6/23/2016
Univ of Washington
mi
from
Seattle, WA
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
Status: Enrolling
Updated: 6/23/2016
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated:  7/12/2016
Kyowa PD Site
mi
from
Phoenix, AZ
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated: 7/12/2016
Kyowa PD Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated:  7/12/2016
Kyowa PD Site
mi
from
Sun City, AZ
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated: 7/12/2016
Kyowa PD Site
mi
from
Sun City, AZ
Click here to add this to my saved trials
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated:  7/12/2016
Kyowa PD Site
mi
from
Tucson, AZ
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated: 7/12/2016
Kyowa PD Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated:  7/12/2016
Kyowa PD Site
mi
from
Fountain Valley, CA
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated: 7/12/2016
Kyowa PD Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated:  7/12/2016
Kyowa PD Site
mi
from
Irvine, CA
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated: 7/12/2016
Kyowa PD Site
mi
from
Irvine, CA
Click here to add this to my saved trials
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated:  7/12/2016
Kyowa PD Site
mi
from
Los Angeles, CA
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated: 7/12/2016
Kyowa PD Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated:  7/12/2016
Kyowa PD Site
mi
from
Oxnard, CA
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated: 7/12/2016
Kyowa PD Site
mi
from
Oxnard, CA
Click here to add this to my saved trials
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated:  7/12/2016
Kyowa PD Site
mi
from
Pasadena, CA
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated: 7/12/2016
Kyowa PD Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated:  7/12/2016
Kyowa PD Site
mi
from
Reseda, CA
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated: 7/12/2016
Kyowa PD Site
mi
from
Reseda, CA
Click here to add this to my saved trials
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated:  7/12/2016
Kyowa PD Site
mi
from
Sunnyvale, CA
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated: 7/12/2016
Kyowa PD Site
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated:  7/12/2016
Kyowa PD Site
mi
from
Torrance, CA
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated: 7/12/2016
Kyowa PD Site
mi
from
Torrance, CA
Click here to add this to my saved trials
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated:  7/12/2016
Kyowa PD Site
mi
from
Englewood, CO
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Status: Enrolling
Updated: 7/12/2016
Kyowa PD Site
mi
from
Englewood, CO
Click here to add this to my saved trials